TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
32 hedge funds and large institutions have $22.5M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
23% more funds holding
Funds holding: 26 → 32 (+6)
20% more capital invested
Capital invested by funds: $18.7M → $22.5M (+$3.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.49M |
| 2 |
Renaissance Technologies
New York
|
+$337K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$262K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$231K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$88.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$553K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$97K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$88.1K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$79K |
| 5 |
VF
Virtu Financial
New York
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RHBC
26
R.H. Bluestein & Co
Birmingham,
Michigan
| $34K | -$18.1K | -30 | -38% |
|
27
JP Morgan Chase
New York
| $34K | +$21.7K | +36 | +257% |
|
28
UBS Group
Zurich,
Switzerland
| $31K | +$6.04K | +10 | +27% |
|
29
Macquarie Group
Sydney, NSW 2000,
Australia
| $9K | +$8.45K | +14 | New |
|
|
CHP
30
Cable Hill Partners
Portland,
Oregon
| $7K | +$3.02K | +5 | +100% |
|
31
Wells Fargo
San Francisco,
California
| $5K | -$21.1K | -35 | -83% |
|
|
PWM
32
Perigon Wealth Management
San Francisco,
California
| $1K | – | – | – |
|
|
33
Stifel Financial
St. Louis,
Missouri
| – | -$97K | -154 | Closed |
|
|
34
Creative Planning
Overland Park,
Kansas
| – | -$79K | -125 | Closed |
|
35
Bank of America
Charlotte,
North Carolina
| – | -$16K | -25 | Closed |
|
TCON Hedge Fund Activity: Q4 2017 in Review
32 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2017, worth a combined $22.5M — up 20% from $18.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TCON positions and 3 closed out — a net gain of 6 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $1.49M. The largest seller was QVT Financial, cutting an estimated $553K.
- 32 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2017, up from 26 in Q3 2017.
- Funds reported $22.5M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 20% quarter-over-quarter.
- 9 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 3 closed out, a net change of +6 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was 683 Capital Management, an estimated $1.49M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was QVT Financial, an estimated $553K sold.
Based on aggregated 13F filings for Q4 2017.